Identification

Name
Scopolamine
Accession Number
DB00747  (APRD00616)
Type
Small Molecule
Groups
Approved, Investigational
Description

An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]

Structure
Thumb
Synonyms
  • (-)-hyoscine
  • (-)-scopolamine
  • (1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
  • 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate
  • 6,7-Epoxytropine tropate
  • alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
  • Hyoscine
  • scopine (-)-tropate
  • scopine (−)-tropate
  • Scopolamine hydrobromide
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Hydrobromide InjectionLiquid0.6 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-07-08Not applicableCanada
Scopolamine Hydrobromide InjectionLiquid0.4 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-05-31Not applicableCanada
Scopolamine Hydrobromide Injection USPSolution0.6 mgIntramuscular; Intravenous; SubcutaneousPfizer1981-12-31Not applicableCanada
Scopolamine Hydrobromide Injection USPSolution0.4 mgIntramuscular; Intravenous; SubcutaneousPfizer1981-12-31Not applicableCanada
Transderm ScopPatch, extended release1 mg/3dTransdermalPhysicians Total Care, Inc.2007-10-02Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalBaxter Laboratories2003-01-01Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalNovartis2007-10-02Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalSandoz2016-12-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Trandermal SystemPatch, extended release1 mg/1TransdermalPerrigo New York Inc.2017-06-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Diban CapScopolamine (3.3 mcg) + Atropine Sulfate (9.7 mcg) + Attapulgite (300 mg) + Hyoscyamine sulfate (0.0519 mg) + Opium (12 mg) + Pectin (71.4 mg)CapsuleOralWyeth Ayerst Canada Inc.1998-02-182001-01-30Canada
Diban CapScopolamine (3.3 mcg) + Atropine Sulfate (9.7 mcg) + Attapulgite (300 mg) + Hyoscyamine sulfate (0.0519 mg) + Opium (12 mg) + Pectin (71.4 mg)CapsuleOralAyerst Laboratories1992-12-311999-04-12Canada
Donnagel LiqScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Kaolin (6 g) + Pectin (142.8 mg)LiquidOralWyeth Ayerst Canada Inc.1995-12-311997-08-14Canada
Donnagel LiqScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Kaolin (6 g) + Pectin (142.8 mg)LiquidOralAyerst Laboratories1993-12-311996-09-10Canada
Donnatal ElixirScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)ElixirOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal ElixirScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)ElixirOralWyeth Ayerst Canada Inc.1994-12-312001-01-16Canada
Donnatal ExtentabsScopolamine (0.0195 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Phenobarbital (48.6 mg)Tablet, extended releaseOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal Extentabs SrtScopolamine (0.0195 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Phenobarbital (48.6 mg)Tablet, extended releaseOralWyeth Ayerst Canada Inc.1994-12-312001-05-07Canada
Donnatal TabScopolamine (6.5 mcg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Phenobarbital (16.2 mg)TabletOralWyeth Ayerst Canada Inc.1994-12-312001-05-22Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Atenolol ScopolamineScopolamine (.25 mg/25.25mg) + Atenolol (25 mg/25.25mg)TabletBuccal; Oral; Sublingual; TransmucosalTPS2014-10-01Not applicableUs
Atenolol ScopolamineScopolamine (.5 mg/50.5mg) + Atenolol (50 mg/50.5mg)TabletOralTPS2014-10-01Not applicableUs
B-DonnaScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralWinder Laboratories, LLC2015-12-302016-03-11Us
Belladonna Alkaloids with PhenobarbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralWest Ward Pharmaceutical1966-01-01Not applicableUs0143 114020170720 1564 4ev749
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralRebel Distributors2004-08-31Not applicableUs
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralLiberty Pharmaceuticals, Inc.2000-12-01Not applicableUs00143 1140 10 nlmimage10 bb045dd2
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralLegacy Pharmaceutical Packaging2000-12-01Not applicableUs
Belladonna Alkaloids with PhenobartbitalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralApace Packaging2000-12-012018-03-22Us
DonnatalScopolamine (.0065 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Phenobarbital (16.2 mg/1)TabletOralCarilion Materials Management2008-05-07Not applicableUs
DonnatalScopolamine (.0065 mg/5mL) + Atropine Sulfate (.0194 mg/5mL) + Hyoscyamine sulfate (.1037 mg/5mL) + Phenobarbital (16.2 mg/5mL)ElixirOralConcordia Pharmaceuticals, Inc1980-12-30Not applicableUs
International/Other Brands
Scopoderm / Transderm-Scop (Novartis)
Categories
UNII
DL48G20X8X
CAS number
51-34-3
Weight
Average: 303.3529
Monoisotopic: 303.147058165
Chemical Formula
C17H21NO4
InChI Key
STECJAGHUSJQJN-FWXGHANASA-N
InChI
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.

Associated Conditions
Associated Therapies
Pharmacodynamics

Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.

Mechanism of action

Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
USucrase-isomaltase, intestinal
inhibitor
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHuman
Absorption

Bioavailability is 10 - 50%

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Less than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.

Half life

4.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when Scopolamine is combined with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
1,10-PhenanthrolineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Scopolamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Adipiplon.Investigational
AgmatineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Agomelatine.Approved, Investigational
Ajulemic acidThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Ajulemic acid.Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Scopolamine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.Approved
AmikacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Amphetamine.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aniracetam.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Anisotropine Methylbromide.Approved
APD791The risk or severity of adverse effects can be increased when Scopolamine is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Scopolamine is combined with AZD-3043.Investigational
AzelastineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Scopolamine.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Barbituric acid derivative.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.Approved
BenziloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzilone.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzquinamide.Withdrawn
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Scopolamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzyl alcohol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Scopolamine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Scopolamine.Approved
BL-1020The risk or severity of adverse effects can be increased when Scopolamine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Blonanserin.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bornaprine.Experimental
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Buclizine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bufotenine.Experimental, Illicit
BuprenorphineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Scopolamine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Camylofin.Experimental
CannabidiolThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Scopolamine is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Scopolamine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Scopolamine.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Caroxazone.Withdrawn
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Scopolamine.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cathinone.Illicit
CerlapirdineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.Approved
CilansetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cilansetron.Investigational
CimetropiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cimetropium.Experimental, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Scopolamine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Scopolamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Scopolamine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Colistin.Approved
CoumaphosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Coumaphos.Vet Approved
CP-945598The risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with CP-945598.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cycrimine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Scopolamine.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Darifenacin.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Deanol.Experimental
DecamethoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Delorazepam.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Scopolamine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dichloralphenazone.Approved, Illicit
DichlorvosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diethyl ether.Experimental
DifemerineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Difemerine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Difenoxin.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihexyverine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Scopolamine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimetindene.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphemanil.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Scopolamine.Approved, Illicit
DisopyramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Disopyramide.Approved
DistigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Scopolamine.Approved
DolasetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Domoic Acid.Experimental
DonepezilThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Scopolamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dyclonine.Approved
EchothiophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Edivoxetine.Investigational
EdrophoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of constipation can be increased when Scopolamine is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Epinastine.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Scopolamine.Experimental
EplivanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etacrynic acid.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etanautine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethadione.Experimental
EthanolScopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etybenzatropine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fenpiverinium.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Scopolamine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Fenthion.Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flavoxate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Scopolamine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gaboxadol.Investigational
GalantamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Scopolamine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Scopolamine is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantScopolamine may increase the gastrointestinal motility reducing activities of Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Scopolamine.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GranisetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.Approved, Investigational
GW842166The risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with GW842166.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexocyclium.Approved
HomatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine Methylbromide.Approved
Huperzine AThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Huperzine A.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
HydrocodoneScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Scopolamine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hyoscyamine.Approved
HypericinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hypericin.Investigational
IbipinabantThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Ibipinabant.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Imagabalin.Investigational
ImidafenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Imidafenacin.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indiplon.Investigational
IpidacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Scopolamine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsopropamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Isopropamide.Approved, Vet Approved
ItoprideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Itopride.Investigational
KanamycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ketobemidone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Scopolamine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Scopolamine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Scopolamine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Scopolamine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Scopolamine.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Scopolamine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Linezolid.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Scopolamine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lormetazepam.Approved
LortalamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Scopolamine.Approved, Investigational
LumateperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Scopolamine.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium chloride.Approved
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Scopolamine.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Scopolamine.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium orotate.Experimental
Magnesium oxideThe therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Scopolamine.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Scopolamine.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Malathion.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Scopolamine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mazaticol.Experimental
MazindolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mebanazine.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mebeverine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Melperone.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mepenzolate.Approved
MephenesinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.Approved
MethotrimeprazineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methscopolamine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Scopolamine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylscopolamine bromide.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methysergide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.Approved
MetyrosineScopolamine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Scopolamine.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Scopolamine.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Scopolamine.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
MirabegronThe risk or severity of urinary retention can be increased when Scopolamine is combined with Mirabegron.Approved
MirtazapineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Scopolamine is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Scopolamine is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Scopolamine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Scopolamine is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Nabiximols.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Scopolamine.Approved
NaltrexoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nefiracetam.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Neosaxitoxin.Investigational
NeostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nicomorphine.Experimental
NisoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Scopolamine.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Scopolamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Opium.Approved, Illicit
OrphenadrineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Otilonium.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxitropium.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Scopolamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Scopolamine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxyphencyclimine.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Scopolamine.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxyphenonium.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.Approved
PalmidrolThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Palmidrol.Experimental, Nutraceutical
PalonosetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.Approved
ParaldehydeScopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paramethadione.Approved
ParaoxonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Paraoxon.Experimental
PargylineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Scopolamine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Scopolamine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Scopolamine.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Penthienate.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Scopolamine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenglutarimide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Scopolamine.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Scopolamine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Scopolamine.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.Approved
PinazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipenzolate.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piperidolate.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pirlindole.Approved
PivagabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Scopolamine.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Scopolamine.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Poldine.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Scopolamine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Scopolamine.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pomalidomide.Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Scopolamine.Approved, Investigational
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Scopolamine is combined with Potassium Chloride.Approved, Withdrawn
PramipexoleScopolamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Scopolamine.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Prifinium.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Scopolamine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Proxibarbal.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Scopolamine.Approved
PRX-08066The risk or severity of adverse effects can be increased when Scopolamine is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of constipation can be increased when Scopolamine is combined with Ramosetron.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Scopolamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Scopolamine.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Revefenacin.Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ribostamycin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Riluzole.Approved, Investigational
RimonabantThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Rimonabant.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ritanserin.Investigational
RivastigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rizatriptan.Approved
RociverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rociverine.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Romifidine.Vet Approved
RopiniroleScopolamine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineScopolamine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Scopolamine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Safrazine.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sarpogrelate.Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Secretin human can be decreased when used in combination with Scopolamine.Approved
Secretin porcineThe therapeutic efficacy of Secretin porcine can be decreased when used in combination with Scopolamine.Approved
SelegilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Scopolamine.Approved
SerotoninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sisomicin.Investigational
SLV319The risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with SLV319.Investigational
Sodium oxybateScopolamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Scopolamine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Scopolamine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Scopolamine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Scopolamine.Approved
St. John's WortThe risk or severity of adverse effects can be increased when Scopolamine is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.Approved, Investigational
SulpirideScopolamine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sumatriptan.Approved, Investigational
SurinabantThe risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with Surinabant.Investigational
SuvorexantScopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TalbutalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Scopolamine is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tedizolid phosphate.Approved
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Scopolamine.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.Approved, Investigational
TerfenadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Terfenadine.Approved, Withdrawn
TetracyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrodotoxin.Investigational
ThalidomideScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Thonzylamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiapride.Approved, Investigational
Tiemonium iodideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiemonium iodide.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tilidine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Timepidium.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Scopolamine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Scopolamine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Scopolamine is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tridihexethyl.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethadione.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trospium.Approved
TubocurarineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Umeclidinium.Approved
UrapidilThe risk or severity of adverse effects can be increased when Scopolamine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Scopolamine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Scopolamine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vinylbital.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Scopolamine is combined with WIN 55212-2.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Scopolamine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Scopolamine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zolmitriptan.Approved, Investigational
ZolpidemScopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Scopolamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Yang Guodong, "Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent." U.S. Patent US5543407, issued February, 1993.

US5543407
General References
  1. Putcha L, Cintron NM, Tsui J, Vanderploeg JM, Kramer WG: Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989 Jun;6(6):481-5. [PubMed:2762223]
External Links
Human Metabolome Database
HMDB0003573
KEGG Drug
D00138
KEGG Compound
C01851
PubChem Compound
3000322
PubChem Substance
46506966
ChemSpider
10194106
BindingDB
50015720
ChEBI
16794
ChEMBL
CHEMBL569713
Therapeutic Targets Database
DNC000757
PharmGKB
PA451308
IUPHAR
330
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Scopolamine
ATC Codes
S01FA02 — ScopolamineA04AD01 — ScopolamineA04AD51 — Scopolamine, combinationsN05CM05 — Scopolamine
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (686 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionAlzheimer's Disease (AD) / Dementias1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedDiagnosticUsing Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination1
1CompletedTreatmentAlzheimer's Disease (AD) / Memory Disturbances1
1CompletedTreatmentDementias1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentSocial Anxiety Disorder (SAD)1
1, 2CompletedTreatmentSialorrhea1
2CompletedPreventionMotion Sickness1
2Not Yet RecruitingTreatmentAnalgesia, Obstetrical1
2TerminatedTreatmentDepression, Bipolar / Unipolar Depression1
2, 3CompletedNot AvailableLabour Pain1
2, 3TerminatedTreatmentMotion Sickness1
4CompletedBasic ScienceHealthy Volunteers1
4Not Yet RecruitingTreatmentPatients1
4RecruitingOtherDrug Reaction1
4RecruitingPreventionLaparoscopic Sleeve Gastrectomy / Prophylaxis against postoperative nausea and vomiting1
4RecruitingPreventionNausea / Satisfaction / Vomiting1
4RecruitingTreatmentDepression1
4RecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedNot AvailableCholinergic Function1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedDiagnosticAD1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedSupportive CareNausea / Vomiting1
Not AvailableCompletedTreatmentNausea / Vomiting1
Not AvailableRecruitingDiagnosticGastrointestinal Imaging With pCLE1
Not AvailableUnknown StatusPreventionSimulator Sickness1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableWithdrawnTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
  • Boca pharmacal inc
  • Private formulations inc
Packagers
  • A. Aarons Inc.
  • Adamis Laboratories
  • Advanced Pharmaceutical Services Inc.
  • Alcon Laboratories
  • Alza Corp.
  • Amend
  • Apace Packaging
  • Apotheca Inc.
  • APP Pharmaceuticals
  • Aristos Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Auriga Pharmaceuticals LLC
  • Bausch & Lomb Inc.
  • Baxter International Inc.
  • Boca Pharmacal
  • Bradley Pharmaceuticals Inc.
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Burel Pharmaceuticals Inc.
  • C.O. Truxton Inc.
  • Carwin Associates Inc.
  • Central Texas Community Health Centers
  • Contract Pharm
  • Cornerstone Pharmacy
  • Corvit Pharmaceuticals
  • Dexo LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • H.J. Harkins Co. Inc.
  • Hawthorn Pharmaceuticals
  • Hope Pharmaceuticals
  • Irisys Inc.
  • Kaiser Foundation Hospital
  • Kenwood Labs
  • Kraft Pharmaceutical Co. Inc.
  • Kylemore Pharmaceuticals
  • Larken Laboratories Inc.
  • Liberty Pharmaceuticals
  • Llorens Pharmaceutical
  • Magna Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medi Rx Pharmaceutical Inc.
  • Mikart Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nexgen Pharma Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Patient First Corp.
  • PBM Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Provident Pharmaceuticals LLC
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • River's Edge Pharmaceuticals
  • Sandhills Packaging Inc.
  • SJ Pharmaceuticals LLC
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • Trigen Laboratories Inc.
  • United Research Laboratories Inc.
  • Veratex Corp.
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletBuccal; Oral; Sublingual; Transmucosal
CapsuleOral
LiquidOral
TabletOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous.4 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous0.4 mg
LiquidIntramuscular; Intravenous; Subcutaneous0.6 mg
SolutionIntramuscular; Intravenous; Subcutaneous0.4 mg
SolutionIntramuscular; Intravenous; Subcutaneous0.6 mg
Patch, extended releaseTransdermal1 mg/1
ElixirOral
Patch, extended releaseTransdermal1 mg/3d
Prices
Unit descriptionCostUnit
Oscion Cleanser 6% Lotion 340.2 gm Bottle88.56USD bottle
Oscion Cleanser 3% Lotion 340.2 gm Bottle85.69USD bottle
Isopto Hyoscine 0.25% Solution 5ml Bottle30.99USD bottle
Transderm-Scop 1.5 mg (1 Box Contains 4 Patches)14.87USD patch
Transderm-Scop 1.5 mg (1 Box Contains 10 Patches)12.04USD patch
Transderm-scop 1.5 mg/72hr12.01USD each
Scopolamine hbr crystals6.86USD g
Isopto hyoscine 0.25% drops5.59USD ml
Scopolamine 0.4 mg/ml vial5.4USD ml
Buscopan 20 mg/ml4.5USD ml
Pamine forte 5 mg tablet3.9USD tablet
Pamine 2.5 mg tablet2.66USD tablet
Methscopolamine Bromide 5 mg tablet2.17USD tablet
Methscopolamine brom 5 mg tablet2.09USD tablet
Methscopolamine Bromide 2.5 mg tablet1.67USD tablet
Methscopolamine brom 2.5 mg tablet1.61USD tablet
Scopace 0.4 mg tablet0.67USD tablet
Buscopan 10 mg Tablet0.34USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)59 °CPhysProp
water solubility1E+005 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.98SANGSTER (1994)
Caco2 permeability-4.93ADME Research, USCD
pKa7.75 (at 25 °C)SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility6.61 mg/mLALOGPS
logP1.4ALOGPS
logP0.89ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)6.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity79.72 m3·mol-1ChemAxon
Polarizability31.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9615
Blood Brain Barrier+0.8218
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5174
P-glycoprotein inhibitor INon-inhibitor0.87
P-glycoprotein inhibitor IINon-inhibitor0.8623
Renal organic cation transporterInhibitor0.531
CYP450 2C9 substrateNon-substrate0.7002
CYP450 2D6 substrateNon-substrate0.7296
CYP450 3A4 substrateSubstrate0.5253
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.927
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9581
BiodegradationNot ready biodegradable0.9073
Rat acute toxicity2.0907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9378
hERG inhibition (predictor II)Non-inhibitor0.9167
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0009000000-9733effdc3262b114ed6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0809000000-a686e4c768aedb57cf8e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-1901000000-f66f538c7db471e86fd5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-3900000000-5eedeba4bedea55de9ad
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udr-7900000000-1309364bbca3810a6afa
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0900000000-1c1d2f52fb7a5d745e1e

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Piperidines / Benzene and substituted derivatives / Morpholines / N-alkylpyrrolidines / Trialkylamines / Amino acids and derivatives / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers
show 7 more
Substituents
Beta-hydroxy acid / Monocyclic benzene moiety / Morpholine / Oxazinane / Piperidine / N-alkylpyrrolidine / Benzenoid / Pyrrolidine / Amino acid or derivatives / Carboxylic acid ester
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, epoxide, propanoate ester, tropane alkaloid (CHEBI:16794)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Murasaki O, Kaibara M, Nagase Y, Mitarai S, Doi Y, Sumikawa K, Taniyama K: Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. J Pharmacol Exp Ther. 2003 Dec;307(3):995-1000. Epub 2003 Oct 8. [PubMed:14534362]
  2. Klinkenberg I, Blokland A: The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50. doi: 10.1016/j.neubiorev.2010.04.001. Epub 2010 Apr 14. [PubMed:20398692]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sucrose alpha-glucosidase activity
Specific Function
Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.
Gene Name
SI
Uniprot ID
P14410
Uniprot Name
Sucrase-isomaltase, intestinal
Molecular Weight
209451.49 Da
References
  1. Minai-Tehrani D, Fooladi N, Minoui S, Sobhani-Damavandifar Z, Aavani T, Heydarzadeh S, Attar F, Ghaffari M, Nazem H: Structural changes and inhibition of sucrase after binding of scopolamine. Eur J Pharmacol. 2010 Jun 10;635(1-3):23-6. doi: 10.1016/j.ejphar.2010.02.040. Epub 2010 Mar 15. [PubMed:20230815]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, Rollema H: The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol. 2005 Jan 4;506(3):209-19. Epub 2004 Dec 15. [PubMed:15627430]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP: Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. [PubMed:15733544]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP: Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. [PubMed:15733544]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:24